engleski

Pentoxifylline treated MID patients ; results of a European double-blind placebo-controlled multicentre study

In 29 European centers, 289 patients who met MID criteria according to DSM-III-R were enrolled. All patients had CT scan with at least one ischaemic lesion compatible with the diagnosis of MID, a Hachinski score of at least 7 and Mini Mental State examination between 10-25. The study was randomized and double-blind, 148 patients were on pentoxifylline and 141 on placebo, 47 patients dropped out before the end of the study. The Gottfries-Brane-Steen (GBS) scale was the primary efficacy criterion. The overall score£ improved by 0.7 points in the placebo group and by 3.5 points in the pentoxifylline group (p = 0.028). The subscore for intellectual function improved by 0.4 points in the placebo-treated patients and by 1.6 in the pentoxifylline group (p = 0.013). The total score of the SCAG showed an improvement of 4.2 points in the pentoxlfylline group and 2.6 points in the placebo group (p = 0.025). The cognitive function score improved by 1.7 points on trial medication and 0.5 on placebo (p = 0.005). The global ratings by relatives resulted in a significant difference after 3 and 6 months (p=0.050 after 3 months, p = 0.023 after 6 months and p = 0.090 after 9 months). According to the above mentioned results, we can conclude that this study demonstrates the efficacy of pentoxifylline in patients with multi-infarct dementia.

clinical trial; double-blind; pentoxifylline

nije evidentirano